产后哺乳期华法林剂量需求增加一例报告
本文报告一例40岁女性产后2个月哺乳期间从依诺肝素单药治疗转回华法林,尽管恢复既往治疗剂量,INR仍持续低于治疗范围,需多次增量,最终产后华法林剂量较孕前增加100%才达到治疗INR。提示产后尤其哺乳期患者可能需要更高华法林剂量,临床应密切监测并调整剂量。
要点
- 产后哺乳期恢复华法林时,既往治疗剂量可能不足以维持治疗INR。
- 该患者产后华法林剂量较孕前增加100%才达到治疗INR。
- 临床应密切监测产后哺乳期华法林患者的INR并及时调整剂量。
核心结论
- 产后尤其哺乳期患者可能需要较孕前更高的华法林剂量以达到治疗INR。
研究设计与样本
- 个案报告:一例40岁女性产后2个月哺乳期间从依诺肝素单药治疗转回华法林。
主要发现
- 恢复既往治疗剂量华法林后INR仍持续低于治疗范围,需多次增量。
- 最终产后华法林剂量较孕前增加100%才达到治疗INR。
临床怎么用
- 临床应密切监测产后哺乳期华法林患者的INR,必要时调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Warfarin is the only oral anticoagulant recommended in women who are breastfeeding. Although warfarin is a compatible and recommended agent in the postpartum period and during lactation, little is known regarding changes to warfarin dose requirements in this patient population. Here, we report the case of a 40-year-old woman who transitioned from enoxaparin monotherapy back to warfarin at 2 months postpartum, while she was breastfeeding. Despite resuming warfarin at her previously therapeutic dose, her international normalized ratio (INR) remained subtherapeutic and required multiple dose increases. She ultimately required a 100% increase in her warfarin dose postpartum, compared to pre-pregnancy, to achieve a therapeutic INR. This case suggests patients may require higher warfarin doses postpartum, compared to pre-pregnancy, especially if breastfeeding. Clinicians should closely monitor these patients and adjust warfarin doses as necessary.
引用
- Uppuluri E, Idrees N, Shapiro N, et al. Warfarin dosage in a postpartum woman while breastfeeding: A case report. Pharmacotherapy. 2024. PMID: 38634189. doi:10.1002/phar.2917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。